EUVIMEDEUVIMED entdecken
Crossref

Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia

Anna Ruiz-Llobet, Susanna Gassiot, Edurne Sarrate, Josune Zubicaray, Susana Rives, Warda Suleman, Rubén Berrueco

Thrombosis and Haemostasis · 2024-10 · 124 (10) · 973-985

DOI: 10.1055/a-2316-4547 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 17.05.2024. Verfasst von Anna Ruiz-Llobet und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology Department, Hospital Sant Joan de Déu Barcelona, Institut de Recerca Pediàtrica, Hospital San Joan de Déu de Barcelona (IRP-HSJD…. Hauptthemen laut MEDLINE: Asparaginase, Thrombin, Venous Thromboembolism, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Venous thromboembolism (VTE) etiology in children with acute lymphoblastic leukemia (ALL) is multifactorial. The use of global assays of hemostasis as a thrombin generation test (TGT) is useful to individualize VTE risk in adult patients. This prospective cohort study aimed to evaluate the usefulness of an automated TGT to evaluate VTE risk during ALL treatment in children.

Methods

TGT (automated analyzer ST Genesia; ThromboScreen) and pro- and anticoagulant plasma proteins were analyzed during ALL treatment in pediatric patients following LAL-SEHOP-PETHEMA-2013 guidelines. Results were compared with a series of pediatric normal controls and evaluated according to pegylated asparaginase PEG-ASP administration and to VTE risk factors.

Results

The study included 67 patients: males n = 35, B-ALL (n = 60). None had a VTE during the evaluated period. Compared to healthy controls, the normalized endogenous thrombin potential (N-ETP) ratio in patients was higher and ETP inhibition (ETP-inh) was lower, especially after PEG-ASP administration. Plasmatic protein C and protein S levels decreased after PEG-ASP administration, but antithrombin mean level did not. A bivariant analysis showed that ETP-inh was lower in patients >10 years old (p = 0.05) and in those with non-O blood type (p = 0.005). A linear mixed model also showed a higher TGT prothrombotic profile in patients with inherited thrombophilia.

Conclusion

TGT could be a biomarker of a high VTE risk in ALL pediatric patients. Non-O blood group and inherited thrombophilia were associated with a significantly higher thrombotic profile, and an increased profile was also observed after administration of PEG-ASP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsparaginaseThrombinVenous ThromboembolismPrecursor Cell Lymphoblastic Leukemia-LymphomaPolyethylene GlycolsHumansMaleFemaleChildAdolescentChild, PreschoolProspective StudiesRisk FactorsBlood Coagulation TestsInfantBlood CoagulationCase-Control StudiesAntineoplastic Agents

Substanzen

AsparaginaseThrombinpegaspargasePolyethylene GlycolsAntineoplastic Agents

Autor:innen und Institutionen

  • Pediatric Hematology Department, Hospital Sant Joan de Déu Barcelona, Institut de Recerca Pediàtrica, Hospital San Joan de Déu de Barcelona (IRP-HSJD), Esplugues de Llobregat, Universitat de Barcelona, Barcelona, Spain.
  • Instituto Nacional de Investigación Biomédica en Enfermedades Raras (CIBER ER), Instituto de Salud Carlos III, Madrid, Spain.
  • Laboratory of Hematology, Hospital Sant Joan de Déu Barcelona, Institut de Recerca Pediàtrica, Hospital San Joan de Déu de Barcelona (IRP-HSJD), Esplugues de Llobregat, Universitat de Barcelona, Barcelona, Spain.
  • Servicio de Hematología y Hemoterapia, Hematología y Oncología Pediátricas, Hospital Infantil Universitario Niño Jesús, Fundación para la Investigación Biomédica del Hospital Infantil Universitario Niño Jesús, Madrid, S…
  • Hematology and Oncology, Leukemia and Lymphoma Department, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu de Barcelona, Esplugues de Llobregat, Institut de Recerca Pediàtrica, Hospital San Joan de Déu de B…

Förderung

  • Instituto de Salud Carlos III
  • Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España

Zitieren

APA

Ruiz-Llobet, A., Gassiot, S., Sarrate, E., Zubicaray, J., Rives, S., Suleman, W., & Berrueco, R. (2024). Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia. Thrombosis and Haemostasis, 124(10), 973-985. https://doi.org/10.1055/a-2316-4547

Vancouver

Ruiz-Llobet A, Gassiot S, Sarrate E, Zubicaray J, Rives S, Suleman W, et al. Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia. Thrombosis and Haemostasis. 2024;124(10):973-985. doi:10.1055/a-2316-4547

BibTeX
@article{RuizLlobet2024,
  author = {Ruiz-Llobet, Anna and Gassiot, Susanna and Sarrate, Edurne and Zubicaray, Josune and Rives, Susana and Suleman, Warda and Berrueco, Rubén},
  title = {Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {10},
  pages = {973--985},
  doi = {10.1055/a-2316-4547}
}
Kostenlos starten →